2 results
Approved WMOCompleted
Primary:* To determine the efficacy profile of PA101 delivered via a high efficiency nebulizer (eFlow®,PARI) in comparison with placebo following 6 weeks of treatment in patients with indolentsystemic mastocytosis (ISM) who are symptomatic despite…
Approved WMOCompleted
To assess accuracy and reliability of new-to-market CGM systems in patients with type 1 diabetes.